CD33 and acute myeloid leukemia: Approved by the FDA in 2017, GO is indicated for patients with CD33-positive AML based on a phase III ALFA-0701 trial, which demonstrated that a reduced dose of GO with standard chemotherapy improved survival in adults with AML [117].